Binosto® (buffered alendronate sodium 70mg) is an effervescent tablet for oral solution for the treatment of osteoporosis – taken just once a week, with a reduced volume of water to drink. EffRx created Binosto® by taking this product from start to finish, including benefit assessment, formulation development, clinical development, FDA approval through a 505(b)(2) route, licensing to and launch via commercial partners. The approval and commercial launch of Binosto® provides an important proof-of-concept of EffRx’s go-to-market capabilities. Proprietary Product
In-Licensed Rare Disease Products*
Alkindi® is an immediate-release hydrocortisone preparation that has been specifically designed to meet the dosing needs of adrenal insufficiency.
Bronchitol®, intended for people living with cystic fibrosis, is dry powder mannitol that is inhaled twice daily using a small handheld device.
Efmody® is a modified-release preparation of hydrocortisone specifically designed for the treatment of patients with CAH, a rare condition caused by a genetic deficiency of adrenal enzymes.
Miglustat Dipharma is an inhibitor of glucosylceramide synthase. Its therapeutic areas are Lysosomal Storage Diseases.
*Swiss Market